Citadel Advisors’s LENZ Therapeutics LENZ Stock Holding History

Citadel Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$717K	Sell	78,400 -3,700	-5%	-$52K	﹤0.01%	8445
2025 Q4	$1.31M	Buy	82,100 +57,200	+230%	+$1.67M	﹤0.01%	6805
2025 Q3	$1.16M	Buy	24,900 +14,500	+139%	+$533K	﹤0.01%	7211
2025 Q2	$305K	Buy	+10,400	New	+$283K	﹤0.01%	9784
2024 Q1	–	Sell	-243	Closed	-$4.45K	–	15567
2023 Q4	$4.45K	Buy	243 +172	+242%	+$2.84K	﹤0.01%	13504
2023 Q3	$1.24K	Sell	71 -472	-87%	-$8.21K	﹤0.01%	13893
2023 Q2	$9.88K	Sell	543 -1,028	-65%	-$20.5K	﹤0.01%	13234
2023 Q1	$26.9K	Sell	1,571 -1,600	-50%	-$25.9K	﹤0.01%	12830
2022 Q4	$73.7K	Sell	3,171 -1,929	-38%	-$44.7K	﹤0.01%	11642
2022 Q3	$113K	Buy	5,100 +3,429	+205%	+$81.7K	﹤0.01%	10990
2022 Q2	$32K	Buy	+1,671	New	+$37.3K	﹤0.01%	12186

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Citadel Advisors's LENZ Position: Q1 2026 in Review

Citadel Advisors sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 80,574 shares — an estimated $1.13M sold.

Citadel Advisors first reported a position in LENZ in Q2 2021 and held it in 15 quarters. The position peaked at $38.9M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Citadel Advisors reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 80,574 LENZ Therapeutics shares in Q1 2026, an estimated $1.13M.
Citadel Advisors first reported a position in LENZ Therapeutics in Q2 2021 and held it in 15 quarters.
Citadel Advisors's LENZ Therapeutics position peaked at $38.9M in Q2 2021.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.